

Acknowledgements

The *Medical Eligibility Criteria for Contraceptive Use* and this version of the *Medical Eligibility Criteria Wheel* were developed by the World Health Organization's Department of Reproductive Health and Research. This wheel is based on similar medical eligibility criteria wheels developed independently in Ghana and Jordan. We would like to thank the responsible groups for their innovative work:

- **Ghana:** The Department of Obstetrics and Gynaecology at the Korle Bu Teaching Hospital, part of the University of Ghana Medical School; and the WHO country office in Ghana. Further technical or financial support was provided by: the Ghana Health Service, UNFPA/Ghana, Gold Fields Ghana Ltd., JHPIEGO, EngenderHealth, WHO/AFRO, USAID, and WHO/Eritrea.
- **Jordan:** The Jordan Health Communication Partnership and the Near East Division, led by the late Dr Alfred Yassa, in the Health Communication Partnership at the Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs, in collaboration with the Jordan Ministry of Health, and with support from USAID.

We would like to thank the following individuals for their work on the original wheel: Dr Charles Fleischer-Djoletto, WHO/Ghana; Dr Enyonam Kwawukume, Korle Bu Teaching Hospital; Mr Ward Rinehart of the INFO Project, JHSPH/CCP; Dr Therese Lesikel, WHO/AFRO; Dr Kathryn Curtis, Centers for Disease Control and Prevention; Ms Kathryn Church, Dr Catherine d'Arcangues, Dr Nuriye Ortayli, Ms Sarah Johnson, and Dr Paul Van Look, Department of Reproductive Health and Research, WHO.

Dr Mario Festin, Dr Mary Lyn Gaffield, and Ms Sarah Johnson were responsible for this *2008 Update*.

Layout and design: Ms Cath Hamill and Ms Janet Petitpierre.

Ordering copies and further information

Detailed information on the medical eligibility criteria, including guidance on other contraceptive methods, appears in the *Medical Eligibility Criteria for Contraceptive Use*, 3rd edition, 2004 and the *2008 Update*. This can be accessed at <http://www.who.int/reproductive-health> or copies can be ordered from the address below.

Sample copies of the wheel can be ordered from:
Documentation Centre
Department of Reproductive Health and Research
World Health Organization
1211 Geneva 27
Switzerland
Fax: +41 22 791 4189. Phone: +41 22 791 4447.
Email: rhrpublications@who.int

Bulk orders to supply programmes can be ordered from:
WHO Press
World Health Organization
1211 Geneva 27
Switzerland
Fax: +41 22 791 48 57. Phone: +41 22 791 32 64.
Email: bookorders@who.int
Order online: <http://www.who.int/bookorders>

Conditions that are category 1 and 2 for all methods (method can be used)

Age 18–39	High risk for HIV	Schistosomiasis (bilharzia)
Anaemias, including sickle-cell disease and thalassaemia	History of gestational diabetes	Surgery without prolonged immobilization
Benign ovarian tumors, including cysts	History of high blood pressure during pregnancy	Taking antibiotics (excluding rifampicin/rifabutin)
Breast disease: family history, benign breast disease and undiagnosed mass	History of pelvic surgery, including caesarean section	Thyroid disorders
Depression	Irregular, heavy or prolonged menstrual bleeding	Tuberculosis (but if pelvic, cannot use IUD)
Dysmenorrhoea	Malaria	Uncomplicated valvular heart disease
Endometriosis	Mild cirrhosis	Varicose veins
Epilepsy	Past ectopic pregnancy	Viral hepatitis (carrier or chronic)
	Post-abortion (no sepsis)	

Notes to the conditions

- | | |
|---|--|
| A Can insert copper IUD < 48 hrs after delivery or \geq 4 weeks. | M To check if migraine has aura, ask: "Do you see a bright spot in your vision before bad headaches?" |
| B If she had no subsequent pregnancy, IUD = 2. | N Migraine without aura and < 35 years old, COCs and CICs = 2. |
| C Or other forms of purulent cervicitis. | N Migraine without aura and \geq 35 years old, COCs and CICs = 3. |
| D If she develops this condition while using the IUD, she can keep using it during treatment. | O For complicated diabetes, or having diabetes for more than 20 years, COCs, CICs, DMPA and NET-EN = 3–4. |
| E If at increased risk of STIs or HIV, advise condom use. | P COCs = 3; CICs = 2. |
| F If very high likelihood of exposure to gonorrhoea or chlamydia = 3. | Q Phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine. For lamotrigine COCs/CICs = 3. Other methods = 1. |
| G If on ARV Therapy = 2, except ritonavir-boosted ARVs = 3. | R If she is not clinically well, IUD = 3. |
| H AIDS, but not clinically well on ARV Therapy = 3 for insertion. | S If the uterine cavity is distorted, cannot use IUD. |
| I COCs and heavy smoking = 4. CICs and light smoking = 2. | T > 45 yrs. = 2. |
| J If blood pressure cannot be measured, and she has no known history of hypertension, all methods can be used. | U If established on anticoagulant therapy = 2. |
| K The same category applies to controlled hypertension. | V DMPA = 1; NET-EN = 2. |
| L Risk factors include: older age, smoking, diabetes, hypertension. | |

Developed in collaboration with:



Communication Partnership
for Family Health



Johns Hopkins Center for
Communication Programs



University of Ghana
Medical School

© World Health Organization, 2009

